专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070238732A1 BRIMONIDINE AND TIMOLOL COMPOSITIONS 审中-公开
标题翻译：二氢INE嗪和槲皮素组合物
公开(公告)号：US20070238732A1
公开(公告)日：2007-10-11
申请号：US11681150
申请日：2007-03-01
申请人： Richard Graham , Rhett M. Schiffman , Brent A. Johnson , Patrick M. Hughes
发明人： Richard Graham , Rhett M. Schiffman , Brent A. Johnson , Patrick M. Hughes
IPC分类号： A61K31/5377 , A61K31/4164
CPC分类号： A61K9/0048 , A61K31/4164 , A61K31/498 , A61K31/535 , A61K31/5377 , A61K2300/00
摘要： Disclosed herein are compositions comprising brimonidine and timolol. Methods and medicaments related thereto are also disclosed.
摘要翻译：本文公开了包含溴莫尼定和噻吗洛尔的组合物。还公开了与之相关的方法和药物。

2. 发明申请

US20080318986A1 Ddc Compositions 审中-公开
标题翻译： Ddc组合
公开(公告)号：US20080318986A1
公开(公告)日：2008-12-25
申请号：US11997397
申请日：2006-10-11
申请人： Rhett M. Schiffman , Patrick M. Hughes , Jerald Gordon , Eric Romanowski
发明人： Rhett M. Schiffman , Patrick M. Hughes , Jerald Gordon , Eric Romanowski
IPC分类号： A61K31/513 , A61P27/02 , A61P31/12
CPC分类号： A61K31/7068
摘要： A composition comprising from 1% to 3% dDC which is aqueous and ophthalmically acceptable is disclosed herein.
摘要翻译：本文公开了包含1％至3％水性和眼用可接受性的dDC的组合物。

3. 发明申请

US20100056547A1 OPHTHALMIC COMPOSITIONS COMPRISING dDC 审中-公开
标题翻译：包含dDC的透明组合物
公开(公告)号：US20100056547A1
公开(公告)日：2010-03-04
申请号：US11909479
申请日：2006-03-21
申请人： Patrick M. Hughes , Rhett M. Schiffman , Harold G. Jensen , Joan-En Chang-Lin
发明人： Patrick M. Hughes , Rhett M. Schiffman , Harold G. Jensen , Joan-En Chang-Lin
IPC分类号： A61K31/495 , A61P27/02
CPC分类号： A61K9/0048 , A61K31/7068
摘要： A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein.An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed.An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 μL of dDC is administered to said eye is also disclosed.A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.
摘要翻译：包含dDC和聚合物的组合物，其中所述组合物是具有在与眼表面接触时增加的粘度的水性液体。还公开了包含治疗有效浓度的dDC的水性组合物，其中dDC的浓度小于1％。还公开了包含治疗有效量的dDC的滴眼剂，其中dDC的量小于300μg。还公开了向有效量的dDC局部给予患有病毒性结膜炎的人的眼睛的病毒感染的方法，其中向所述眼睛施用少于300μL的dDC。一种包含组合物和分配器的试剂盒，其中所述分配器分配包含治疗有效量的dDC的液滴，其中dDC的量小于300μg也被公开。

4. 发明授权

US09161970B2 Dermal filler 有权
公开(公告)号：US09161970B2
公开(公告)日：2015-10-20
申请号：US11954602
申请日：2007-12-12
申请人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
发明人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
IPC分类号： A61K47/36 , A61K47/12 , A61K47/10 , A61L27/10 , A61L27/54 , A61L27/20 , A61K38/48 , A61K9/00
CPC分类号： A61K38/4893 , A61K8/64 , A61K8/66 , A61K8/735 , A61K9/0021 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K2800/48 , A61K2800/54 , A61K2800/91 , A61L27/20 , A61L27/54 , A61L2300/252 , A61L2300/602 , A61L2400/06 , A61Q19/08 , C12N9/6489 , C12Y304/24069 , C08L5/08
摘要： Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

5. 发明授权

US09044477B2 Botulinum toxin formulation 有权
标题翻译：肉毒杆菌毒素制剂
公开(公告)号：US09044477B2
公开(公告)日：2015-06-02
申请号：US11954629
申请日：2007-12-12
申请人： Wendy M. Blanda , Roger K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
发明人： Wendy M. Blanda , Roger K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
IPC分类号： A61K38/00 , A61K39/08 , A61K31/728 , A61K38/48 , A61K9/00 , A61K47/36
CPC分类号： A61K38/4893 , A61K9/0019 , A61K9/0024 , A61K47/36 , C12Y304/24069
摘要： Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
摘要翻译：用透明质酸载体配制的肉毒杆菌神经毒素，肉毒杆菌毒素在皮下位置的驻留时间增加，肉毒杆菌毒素诱导的并发症或副作用较少。

6. 发明授权

US08409607B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08409607B2
公开(公告)日：2013-04-02
申请号：US12029425
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

7. 发明授权

US08404267B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08404267B2
公开(公告)日：2013-03-26
申请号：US12029424
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

8. 发明申请

US20130017268A1 PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF 有权
标题翻译： PROSTAGLANDIN和PROSTAMIDE药物输送系统及其内科治疗用途
公开(公告)号：US20130017268A1
公开(公告)日：2013-01-17
申请号：US13596904
申请日：2012-08-28
申请人： Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
发明人： Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
IPC分类号： A61K9/14 , A61P27/06 , A61K31/216
CPC分类号： A61L31/06 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/204 , A61K31/216 , A61K31/557 , A61K31/5575 , A61L31/16
摘要： Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
摘要翻译：生物相容性，生物可侵蚀的植入物和微球体包括拉坦前列素和可生物降解的聚合物，当放置眼内（如进入subtenon空间）治疗青光眼时有效。

9. 发明授权

US08007828B2 Stabilized biodegradable neurotoxin implants 有权
标题翻译：稳定的生物降解神经毒素植入物
公开(公告)号：US08007828B2
公开(公告)日：2011-08-30
申请号：US12577114
申请日：2009-10-09
申请人： Patrick M. Hughes , Orest Olejnik
发明人： Patrick M. Hughes , Orest Olejnik
IPC分类号： A61K9/14
CPC分类号： A61K9/0024 , A61K9/0051 , A61K9/204 , A61K38/4893
摘要： Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.
摘要翻译：提供了可生物降解的神经毒素植入物和制造和使用这种植入物的方法。可生物降解的神经毒素植入物包括神经毒素，可生物降解的聚合物组分和酸度调节组分。当植入物位于患者体内时，可生物降解的聚合物组分有效地控制来自植入物的神经毒素的释放。酸性调节组分有效地将植入物的pH保持在期望的范围内，当植入物位于患者体内时，当植入物生物降解时，稳定神经毒素是有效的。在一个实施方案中，植入物包括肉毒杆菌毒素，可生物降解聚合物，以及衍生生物可降解聚合物的单体或包含单体单元的寡聚物，所述单体基本上与衍生可生物降解聚合物的单体相同，或这些单体和低聚物。低聚物和可生物降解的聚合物可以衍生自单一类型的单体。本文公开的植入物可以施用于需要长时间治疗效果的人或动物患者。

10. 发明申请

US20100222390A1 Methods and Compositions for the Intravenous Administration of Compounds Related to Proton Pump Inhibitors 审中-公开
标题翻译：静脉注射与质子泵抑制剂相关的化合物的方法和组合物
公开(公告)号：US20100222390A1
公开(公告)日：2010-09-02
申请号：US12572552
申请日：2009-10-02
申请人： Patrick M. Hughes
发明人： Patrick M. Hughes
IPC分类号： A61K31/4439 , C07D401/12 , A61P1/04
CPC分类号： A61K9/0014 , A61K31/4439 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/54 , A61K2300/00
摘要： Disclosed herein are liquid compositions comprising a therapeutically effective concentration of a prodrug of a sulfonyl-containing proton pump inhibitor, wherein said compositions have a pH of from 3 to 7.3. Solid compositions related thereto are also disclosed. Methods of delivering a proton pump related thereto are also disclosed. Compositions comprising a second therapeutically active agent are also disclosed herein.
摘要翻译：本文公开了包含治疗有效浓度的含磺酰基的质子泵抑制剂的前药的液体组合物，其中所述组合物的pH为3至7.3。还公开了与其相关的固体组合物。还公开了与其相关的输送质子泵的方法。本文还公开了包含第二治疗活性剂的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式